This is an early clinical milestone with no efficacy data yet. The FDA registration pathway for Alpha DaRT in this indication remains unclear. Monitor for initial ORR data from ADMIRE and any updates from the ReSTART trial. The company has a $1.1B market cap with no revenue, so clinical progress is the primary driver.
Price Chart
Executive Summary
Alpha Tau announced the successful treatment of the first patient in its ADMIRE study, evaluating Alpha DaRT for immunocompromised patients with recurrent cutaneous squamous cell carcinoma (cSCC). The study targets a high-need population with limited treatment options and builds on momentum from the recently completed ReSTART pivotal trial. This is an early clinical milestone with no efficacy data reported.
Key Facts
- First patient treated in ADMIRE study at Banner MD Anderson Cancer Center
- ADMIRE is a prospective, single-arm study enrolling up to 28 immunocompromised patients with recurrent cSCC
- Primary endpoint: objective response rate (ORR) per RECIST v1.1; secondary endpoints include PFS, OS, and local control over 12 months
- ReSTART pivotal trial for recurrent cSCC recently completed patient enrollment
- Immunocompromised patients face 65- to 100-fold higher incidence of cSCC (organ transplant recipients)
Financial Impact
Clinical milestone; no revenue or financial data provided in the filing.
Risk Factors
- Clinical trial failure risk — no efficacy data from ADMIRE reported yet
- Small sample size (up to 28 patients) limits statistical power
- Regulatory approval for Alpha DaRT in this indication is uncertain and likely years away
- Company is pre-revenue with significant operating losses (per 20-F risk factors)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-078138 |
| Document: ea0297988-6k_alpha.htm | 0001213900-26-078138 |
| Document: 0001213900-26-078138-index-headers.html | 0001213900-26-078138 |
| Document: 0001213900-26-078138-index.html | 0001213900-26-078138 |
| Document: 0001213900-26-078138.txt | 0001213900-26-078138 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 6-K | $14.11 $15.19 | ▲ +7.65% | ▲ +7.84% | $14.77 (+4.68%) |
Aug 10, 2026 7w ago | 6-K | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | Press Release | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | 6-K | $13.60 $14.84 | ▲ +9.12% | ▲ +10.03% | $14.77 (+8.60%) |
Jul 21, 2026 10w ago | 6-K | $13.32 $14.26 | ▲ +7.06% | ▲ +4.50% | $14.77 (+10.89%) |
Jul 15, 2026 11w ago | 6-K | $12.46 $13.87 | ▲ +11.32% | ▲ +8.97% | $14.77 (+18.54%) |
Jun 23, 2026 14w ago | 6-K | $10.05 $13.01 | ▲ +29.45% | ▲ +27.52% | $14.77 (+46.97%) |
Jun 3, 2026 17w ago | Press Release | $10.58 $13.23 | ▲ +25.05% | ▲ +26.05% | $14.77 (+39.60%) |
May 11, 2026 20w ago | Press Release | $10.34 $9.19 | ▼ −11.12% | ▼ −10.82% | $14.77 (+42.84%) |
May 8, 2026 21w ago | Press Release | $8.51 $9.35 | ▲ +9.87% | ▲ +9.85% | $14.77 (+73.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access